The Week

TARS.US fell 3.55% this week to close at $73. The S&P 500 slipped 0.27%, leaving the stock about 3.28 percentage points behind the benchmark. The week followed an up-then-down pattern: the stock climbed from Monday through Wednesday, finishing Wednesday at $78.61, then gave back its gains. It hit the week high of $79.10 on Thursday before sliding, and closed near the week low on Friday. Weekly amplitude was 8.12%. Average daily volume of about 1.15m shares ran roughly 63% above its 60-day median, suggesting heavier-than-usual turnover. There were no major company-specific catalysts this week.

Analyst Ratings

Among the 10 firms covering TARS.US, 9 rate it buy and 1 rate it overweight; none of them are at hold, underweight or sell. The consensus rating is strong buy, with a consensus target price of $99.50, implying around 36.3% upside from the current price. The target range of $84 to $116 shows meaningful spread between the low and high ends. Within its industry, the stock ranks 36th out of 203 pharmaceutical names.

The Week Ahead

The macro calendar is relatively busy next week: S&P Global services PMI final and ISM non-manufacturing PMI land on Monday, trade balance figures follow on Tuesday, and EIA weekly crude inventories arrive on Wednesday. No earnings or major company events are currently scheduled. Market watchers may also look for any follow-through after the American Academy of Optometry annual meeting.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.